Lantheus Holdings, Inc.(LNTH)Earnings, Financials & Key RatiosLantheus Holdings, Inc. (LNTH) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the company has successfully reached a 0.00 debt-to-equity ratio, the deceleration of revenue growth to 1.2% suggests that the firm may struggle to justify its current 32.20 P/E multiple without new growth catalysts.
Lantheus Holdings, Inc. (LNTH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Lantheus Holdings, Inc. (LNTH) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $1.46vs $1.25+16.8% | $377Mvs $354M+6.4% |
| Q1 2026 | Feb 26, 2026 | $1.67vs $1.18+41.5% | $407Mvs $367M+10.8% |
| Q4 2025 | Nov 6, 2025 | $1.27vs $1.27+0.0% | $384Mvs $368M+4.4% |
| Q3 2025 | Aug 6, 2025 | $1.57vs $1.64-4.3% | $378Mvs $363M+4.0% |
Recent stock market news and headlines for Lantheus Holdings, Inc. (LNTH)
On Friday, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter to Lantheus Holdings Inc.'s (NASDAQ:LNTH) New Drug Application (NDA) for LNTH-2501 (Gallium 68 edotreotide), a PET diagnostic imaging kit targeting somatostatin receptor-positive neuroendocrine tumors.
The U.S. Food and Drug Administration declined to approve Lantheus Holdings' diagnostic imaging kit for types of cancer tumors, citing unresolved manufacturing-related conditions at a third-party facility, the company said on Friday.
BEDFORD, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for LNTH-2501 (Gallium 68 edotreotide), a PET diagnostic imaging kit targeting somatostatin receptor-positive (SSTR+) neuroendocrine tumors (NETs).
Key metrics vs top competitors for Lantheus Holdings, Inc. (LNTH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $103.41 | $6.73B | 30.33 | 0.5% | 15.15% | 21.45% | — | |
| $219.75 | $32.01B | 23.11 | 9.84% | 27.44% | 24.41% | — | |
| $186.08 | $17.05B | 51.83 | 18.3% | 10.21% | 27.91% | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — | |
| $36.31 | $26.12B | -84.44 | -71.57% | -3629.19% | -6.03% | — | |
| $366.98 | $383.43B | 44.97 | 18.48% | 17.91% | 45.85% | — |
Lantheus Holdings, Inc. (LNTH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Lantheus Holdings, Inc. (LNTH) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 7, 2026·SEC
May 1, 2026·SEC
Feb 26, 2026·SEC
Get notified when LNTH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Lantheus Holdings, Inc. (LNTH) stock FAQ — growth, dividends, profitability & financials explained
Lantheus Holdings, Inc. (LNTH) reported $1.55B in revenue for fiscal year 2025. This represents a 437% increase from $288.1M in 2012.
Lantheus Holdings, Inc. (LNTH) grew revenue by 0.5% over the past year. Growth has been modest.
Yes, Lantheus Holdings, Inc. (LNTH) is profitable, generating $279.0M in net income for fiscal year 2025 (15.2% net margin).
Lantheus Holdings, Inc. (LNTH) has a return on equity (ROE) of 21.4%. This is excellent, indicating efficient use of shareholder capital.
Lantheus Holdings, Inc. (LNTH) generated $371.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
